Delving into the intricate landscape of NSCLC management, the 2022 Targeted Therapies Forum presents a dedicated breakout session on ‘First Line Therapy for BRAF+ and NTRK+ NSCLC’. Join Dr. Seetharamu and Dagogo-Jack as they elucidate the strategies, challenges, and groundbreaking advancements surrounding BRAF and NTRK targeted treatments for non-small cell lung cancer.
A huge shoutout to our esteemed sponsors for their unwavering support: #Novartis, #Janssen, #Blueprintmedicine, #TakedaOncology, #Astrazeneca, #LillyOncology, and #genentech.
Stay at the forefront of oncological innovations by visiting http://cancerGRACE.org/. Join our vibrant community of professionals and enthusiasts, and partake in enriching discussions at https://cancergrace.org/forum.